MetaCap

Abbott Laboratories (ABT)

NYSE: ABTHealth CareBiotechnology: Pharmaceutical PreparationsUSD

103.00-0.87 (-0.84%)

At close: Nov 20, 4:02 PM ET · Delayed 15 min

ABT stock chart

Technical analysis

Key statistics

All statistics
Market cap
$178.39B
Dividend yield
2.45% ($2.52)
Ex-dividend date
Oct 15, 2026
52-week range
81.97 – 129.85
Day range
102.80 – 105.50
Volume / Avg
7.29M / 8.89M
Beta
—

52-week range

$81.97$129.85

ABT stock today

Abbott Laboratories (ABT) closed at $103.00 on Nov 20, down 0.84% (-$0.87), versus the S&P 500's 3.70% decline. Shares are 20.7% below their 52-week high of $129.85, set on Dec 1, 2025 and 25.7% above the 52-week low of $81.97, in the middle of the past year's range. ABT is down 17.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 19.6%.

At 38.4x trailing earnings, Abbott Laboratories trades above the peer-group median of 21.7x. Its forward P/E of 17.3x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Abbott Laboratories pays an annual dividend of $2.52 per share, a 2.45% yield at the current price.

Summary generated from market data by MetaCap's automated system. Methodology

About Abbott Laboratories

Company profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Robert B. Ford
Headquarters
Abbott Park, IL
Employees
122,000
Website
abbott.com

Financial highlights

Full financials

In fiscal 2025, Abbott Laboratories generated $44.33 billion in revenue, up 5.7% from fiscal 2024, its 2nd consecutive year of revenue growth. Net income was $6.52 billion (-51.3% year over year), for a net margin of 14.7% versus a median of 15.9% in the prior 5 years. Gross margin was 56.4% (up from 55.4%) and operating margin 18.2%.

Abbott Laboratories annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$44.33B$41.95B$40.11B$43.65B$43.08B
Growth+5.67%+4.59%-8.12%+1.34%+24.47%
Net income$6.52B$13.40B$5.72B$6.93B$7.07B
EPS (diluted)$3.72$7.64$3.26$3.91$3.94

Analyst forecast

Forecast

Consensus (28 analysts)

buy

Avg. price target

$118.91+15.45%

  • Strong buy 5
  • Buy 18
  • Hold 5
  • Sell 0
  • Strong sell 0

Target range

Low $100.00High $130.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 21, 2026
EPS actual vs est.
$1.42 vs $1.43
Surprise
-0.70%

Dividends

Dividend history
Annual dividend
$2.52
Last payment
$0.63
Ex-dividend date
Oct 15, 2026

ABT news

All ABT news

Abbott Laboratories peers

Health Care sector
ABT peer companies
CompanyPrice% ChgMarket capCompare
NVONovo Nordisk A/S37.82-2.70%$166.69Bvs ABT
PFEPfizer Inc.27.40-0.51%$156.18Bvs ABT
VRTXVertex Pharmaceuticals Incorporated515.02-1.08%$130.58Bvs ABT
BMYBristol-Myers Squibb Company58.80+0.79%$120.19Bvs ABT
SNYSanofi ADS46.52+1.00%$111.70Bvs ABT
GSKGSK plc ADR47.76-0.13%$95.73Bvs ABT
REGNRegeneron Pharmaceuticals Inc.920.69-0.19%$95.24Bvs ABT
AZNAstraZeneca PLC174.35-0.60%$270.40Bvs ABT

Indexes, lists and sector

Abbott Laboratories stock FAQ

What is Abbott Laboratories's stock price today?

ABT last traded at $103.00 as of Nov 20, 4:02 PM EST, down 0.84% on the day. Prices are delayed at least 15 minutes.

Does Abbott Laboratories pay a dividend?

Yes. Abbott Laboratories pays $2.52 per share annually, a 2.45% yield. The most recent dividend of $0.63 had an ex-dividend date of Oct 15, 2026.

What is ABT's P/E ratio?

ABT trades at a trailing P/E ratio of 38.43 and a forward P/E of 17.35, compared with a median of 21.7 for its closest peers.

Is Abbott Laboratories in the S&P 500?

Yes. Abbott Laboratories (ABT) is a constituent of the S&P 500 index.

Who is Abbott Laboratories's CEO?

Mr. Robert B. Ford is the chief executive officer of Abbott Laboratories, which has about 122,000 employees.

Has ABT ever split its stock?

Yes. The most recent ABT stock split was a 10000-for-4798 split on Jan 2, 2013, one of 7 splits on record.

What is the ABT 52-week high?

The 52-week high for ABT is $129.85 and the 52-week low is $81.97. The stock is currently 20.7% below its high.

Compare ABT